Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.
Ann Oncol. 2016 Jul;27(7):1235-41. doi: 10.1093/annonc/mdw145. Epub 2016 Mar 30.
Jacot W1, Firmin N2, Roca L3, Topart D4, Gallet S2, Durigova A2, Mirr S2, Abach L3, Pouderoux S2, D'Hondt V2, Bleuse JP3, Lamy PJ5, Romieu G2.
- The RCT found that 100,000 IU every two weeks is good
- 150,000 IU every two weeks or 100,000 IU weekly would get most Cancer patients >30 ng and many > 40 ng - which should be the minimum target
- Is 50 ng of vitamin D too high, just right, or not enough
- Note: 50 ng is the typical level of traditionally-living Africans
Note: 6 month is also far too long be help during surgery or subsequent BC treatment
Note: Vitamin D becomes even lower after surgery and subsequent treatment of Breast Cancer
- Breast Cancer chemotherapy 2.7 X more likely to be successful if not vitamin D deficient – Dec 2017
- Chemotherapy might be augmented with Vitamin D – Jan 2017
Probably best to use a loading dose prior to surgery (Vitamin D helps with surgery as well)
Can lower the Chemo dose, and thus the damage, if have good vitamin D
- Metastatic Cancer is maybe reduced by vitamin D - 5 articles
- Vitamin D and breast cancer radiation
- Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
- Cancer - After diagnosis category listing has
60 items along with related searches
Breast Cancer Prevention
- Breast Cancer prevented by Vitamin D (most studies concur) – Dec 2017
- Breast Cancer 7.8 times more likely if Vitamin D less than 20 ng (100 women) – May 2017
- So Tell Me . . . What Are You Doing to Prevent Breast Cancer - June 2017
- Do not wait for Breast Cancer to add vitamin D. Vitamin D can prevent it from occuring
A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level. This randomized phase III study assessed the safety and efficacy of a tailored, high-dose, oral vitD supplementation in restoring a normal 25-hydroxy vitD (25OHD) level in this population.
PATIENTS AND METHODS:
Participants received a 6-month conventional (C) vitD and calcium supplementation or a 6-month high-dose oral vitD regimen tailored on the deficiency (T) and a conventional calcium supplementation. The primary end point was the 6-month percentage of 25OHD serum level normalization.
A total of 215 patients including 197 patients with vitD deficiency were recruited, and 195 patients were randomized (T, 100; C, 95). Compliance to the daily oral supplementation was 68.4% and 67% in the C and T arms, respectively. Discontinuous high-dose vitD compliance appeared higher in the T arm (77%). At 6 months, more patients presented with a normalized vitD level in the T arm (30% versus 12.6%; P = 0.003). Supplementation was well tolerated, and no significant difference in the treatment-related toxicity between the two arms was reported. Fifty-two patients without vitD normalization from the C arm switched to the T arm after 6 months. At 12 months, 44% of these patients achieved vitD normalization.
A tailored high-dose oral vitD supplementation safely allows a higher percentage of the serum 25OHD level normalization compared with a conventional regimen in chemotherapy-treated EBC patients. As compliance to a daily oral supplementation remains poor in this setting, an adaptation of the treatment schedule is warranted.
CLINICAL TRIAL NUMBER: NCT01480869. PMID: 27029707 DOI: 10.1093/annonc/mdw145
376 visitors, last modified 31 Dec, 2017, URL: